Conference Call and Webcast Scheduled for 8:30 AM ET
NEW YORK--(BUSINESS WIRE)--May 2, 2019--
UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report
first quarter 2019 financial results on Thursday, May 9, 2019, prior to
the open of the market. The announcement will be followed by a live
audio webcast and conference call at 8:30AM Eastern Time.
The webcast will be made available on the Investors section of the
Company’s website at http://investors.urogen.com.
Following the live audio webcast, a replay will be available on the
Company's website for approximately two weeks.
Live (U.S. / Canada): 1 (888) 771-4371
Live (International): 1
Confirmation number: 48486174
About UroGen Pharma Ltd.
UroGen Pharma Ltd. (Nasdaq:URGN) is a clinical-stage biopharmaceutical
company developing advanced non-surgical treatments to address unmet
needs in the field of urology, with a focus on uro-oncology. UroGen has
developed RTGel™ reverse-thermal hydrogel, a proprietary sustained
release, hydrogel-based platform technology that has the potential to
improve therapeutic profiles of existing drugs. UroGen’s sustained
release technology is designed to enable longer exposure of the urinary
tract tissue to medications, making local therapy a potentially more
effective treatment option. UroGen’s lead investigational candidates,
UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel)
for intravesical instillation, are designed to potentially ablate tumors
by non-surgical means and to treat several forms of non-muscle invasive
urothelial cancer, including low-grade upper tract urothelial cancer and
low-grade non-muscle invasive bladder cancer, respectively. UroGen is
headquartered in New York, NY with operations in Los Angeles,
CA and Israel.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005133/en/
Source: UroGen Pharma Ltd.
Communications & Investor Relations